Catalent Announces Multi-Year Supply Agreement with Aurinia Pharmaceuticals
Through the agreement, Catalent will manufacture LUPKYNIS (voclosporin), Aurinia’s drug for the treatment of adult patients with lupus nephritis, at its pharmaceutical softgel center of excellence in St. Petersburg, FL.
Catalent announced on Feb. 18, 2021 that it has entered into a multi-year commercial supply agreement with Aurinia Pharmaceuticals, a Canadian pharmaceutical company, for LUPKYNIS (voclosporin), a drug for the treatment of adult patients with lupus nephritis, a complication that stems from the autoimmune disease systemic lupus erythematosus.
The drug, which was approved by FDA in January 2021, will be manufactured as a softgel dosage form at Catalent’s pharmaceutical softgel center of excellence in St. Petersburg, FL, Catalent said in a company press release.
“Catalent has a long track record in bringing novel drugs to market and has supported over 80% of all prescription pharmaceutical softgel brand launches in the U[nited] S[tates]. It has nearly 90 years of experience in the formulation and manufacturing of softgels for both pharmaceutical and consumer health products, which it has drawn upon to jointly develop LUPKYNIS with Aurinia,” said Dr. Aris Gennadios, president, Softgel and Oral Technologies, Catalent, in the press release. “We know the benefits that the dosage form offers developers and patients and look forward to working with Aurinia on the commercial production of this innovative therapeutic option for patients with lupus nephritis going forward, having previously partnered on its development.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
